Corvus Pharmaceuticals Valuation
| CRVS Stock | USD 3.94 0.15 3.67% |
At this time, the firm appears to be fairly valued. Corvus Pharmaceuticals shows a prevailing Real Value of $3.78 per share. The current price of the firm is $3.94. Our model approximates the value of Corvus Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 227.94 M, return on equity of -2.0, and Shares Owned By Insiders of 3.61 % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Corvus Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Corvus Pharmaceuticals is based on 3 months time horizon. Increasing Corvus Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Corvus stock is determined by what a typical buyer is willing to pay for full or partial control of Corvus Pharmaceuticals. Since Corvus Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Corvus Stock. However, Corvus Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.94 | Real 3.78 | Hype 3.94 | Naive 4.04 |
The intrinsic value of Corvus Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Corvus Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Corvus Pharmaceuticals helps investors to forecast how Corvus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Corvus Pharmaceuticals more accurately as focusing exclusively on Corvus Pharmaceuticals' fundamentals will not take into account other important factors: Corvus Pharmaceuticals Total Value Analysis
Corvus Pharmaceuticals is currently anticipated to have valuation of 227.94 M with market capitalization of 262.81 M, debt of 1.37 M, and cash on hands of 56.72 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Corvus Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
227.94 M | 262.81 M | 1.37 M | 56.72 M |
Corvus Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Corvus is to check how much profit was generated for every dollar of assets it reports. Corvus Pharmaceuticals shows a negative utilization of assets of -0.28 percent, losing $0.00283 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Corvus Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Corvus Pharmaceuticals Ownership Allocation
Corvus Pharmaceuticals holds a total of 64.26 Million outstanding shares. Over half of Corvus Pharmaceuticals' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Corvus Pharmaceuticals Profitability Analysis
Net Loss for the year was (27.03 M) with profit before overhead, payroll, taxes, and interest of 0.About Corvus Pharmaceuticals Valuation
The stock valuation mechanism determines Corvus Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Corvus Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Corvus Pharmaceuticals. We calculate exposure to Corvus Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Corvus Pharmaceuticals's related companies.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company was incorporated in 2014 and is based in Burlingame, California. Corvus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.
Corvus Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Corvus Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 48 M |
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.